Patents by Inventor Christopher French

Christopher French has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mechanical interlock for switch
    Patent number: 11373814
    Abstract: A mechanical interlock for a switch gear switch. The mechanical interlock includes a base and a slider. The slider is moveable relative to the base between a first position and a second position. The mechanical interlock is configured to lock the position of the switch when the slider is in the second position.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: June 28, 2022
    Assignee: EATON INTELLIGENT POWER LIMITED
    Inventors: Christopher French, Daniel Sims
  • MECHANICAL INTERLOCK FOR SWITCH
    Publication number: 20210202189
    Abstract: A mechanical interlock for a switch gear switch. The mechanical interlock includes a base and a slider. The slider is moveable relative to the base between a first position and a second position. The mechanical interlock is configured to lock the position of the switch when the slider is in the second position.
    Type: Application
    Filed: December 27, 2019
    Publication date: July 1, 2021
    Inventors: Christopher FRENCH, Daniel SIMS
  • NSD3 INHIBITORS FOR TREATMENT OF CANCERS
    Publication number: 20170007595
    Abstract: The present invention relates to the use of NSD3i inhibitors for the treatment of cancer. In particular, the present invention relates to methods, kits and compositions comprising NSD3 inhibitors to treat cancers dependent on NSD3, in particular subjects with NUT midline carcinoma (NMC) and subjects with NSD3/NUT or BRD4/NUT or BRD3/NUT fusion genes, as well as subjects with BRD4-dependent (but NUT-independent cancers). The present invention also relates to methods, kits and compositions comprising BET inhibitors for the treatment of subjects with NSD3/NUT fusion genes. Other aspects of the invention relate to assays and methods to identify an inhibitor of NSD3 which disrupts or decreases the interaction of the NSD3 protein with the ET do main of BRD4.
    Type: Application
    Filed: January 23, 2015
    Publication date: January 12, 2017
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Christopher A. FRENCH, Peter M. HOWLEY, Erica Marlene WALSH MICHEL, Shaila RAHMAN, Simone KUHNLE
  • Treatment of cancers characterized by chromosomal rearrangement of the gene
    Patent number: 8623853
    Abstract: The present invention is directed, inter alia, to methods of treating NUT midline carcinoma (NMC) by administering compounds that promote increased histone acetylation. The invention also includes assay methods for determining the responsiveness of NMC to specific histone deacetylases and other compounds.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: January 7, 2014
    Assignees: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Christopher French, Jon Aster, Matthias Hofer, James Bradner
  • Treatment of Cancers Characterized by Chromosomal Rearrangement of the NUT Gene
    Publication number: 20110213012
    Abstract: The present invention is directed, inter alia, to methods of treating NUT midline carcinoma (NMC) by administering compounds that promote increased histone acetylation. The invention also includes assay methods for determining the responsiveness of NMC to specific histone deacetylases and other compounds.
    Type: Application
    Filed: July 21, 2009
    Publication date: September 1, 2011
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE
    Inventors: Christopher French, Jon Aster, Matthias Hofer, James Bradner